Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

First imported case of Omicron subvariant BA.5 reported in Shanghai
Published on: 2022-05-31
Share to
User Rating: / 0
PoorBest 

The Chinese mainland has reported its first infection of COVID-19 caused by the Omicron BA.5 subvariant, according to a weekly report from the Chinese Center for Disease Control and Prevention (CDC). The patient, who received four doses of COVID-19 vaccine, was diagnosed with the virus after arriving in Shanghai from Uganda in late April.

The patient departed Uganda on April 25 with stopovers in the Netherlands, on April 26, and in South Korea, on April 27, before arriving in Shanghai. The patient recovered and was discharged from the hospital on May 12, according to a report released on Saturday in the CDC Weekly Report.

The Omicron subvariant BA.5, first found in South Africa in February, has increased its prevalence in the country in recent weeks and spread to 19 other countries over a three-month period. The BA.5 subvariant has led to an increase in the number of cases in countries such as Portugal while South Africa has reported a modest increase in hospitalizations since the end of April.

首例奥密克戎变异株BA.5输入上海

5月28日晚,《中国疾病预防控制中心周报(英文)》在线发文报告了我国首例境外输入奥密克戎变异株BA.5感染者的具体情况。

《报告》指出,最近几周,BA.4和BA.5在南非的流行率增加,并在3个月内传播到另外19个国家;BA.5导致一些国家的病例数上升,如葡萄牙,南非也报告自4月底以来住院人数有适度增加。

根据中疾控披露,BA.5序列于2022年3月15日首次上传至全球流感共享数据库,该序列来自于2月25日在南非采集的一名患者的鼻咽拭子。输入上海病例情况于4月25日从乌干达(KL535航班)出发,4月26日在阿姆斯特丹转机,4月27日从韩国首尔转机(KL535航班)。该患者已在中国和乌干达分别接种了四剂抗新冠肺炎疫苗(北京生物制品研究所有限公司)。确诊后,他被转送至上海市公共卫生临床中心接受治疗。经治疗痊愈,5月12日出院。病毒基因测序结果显示,该患者感染了新冠病毒奥密克戎亚型变异毒株BA.5,是我国报告的首例BA.5境外输入感染者。​

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2022 BusinessTianjin.com. All rights reserved.